StockData

BGM Group Ltd. (BGM) KPIs and segments

BGMNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jul 21, 2026Score 9/30
$8.13+0.12 (+1.50%)

Close on Nov 17, 2026Market cap $3.26BP/E –Yield –

KPIs & segments

Operating metrics and segments that drive BGM's business

BGM's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

BGM's fiscal year ends September 30 — Q2 FY25 = CQ1 2025 (calendar quarter).

Periods
Add to chartMetric
Q2 FY25
Q4 FY24
Q2 FY24
Q4 FY23
Q4 FY22
Q4 FY21
Q4 FY20
Q4 FY19
Diversified Pharmaceutical and Allied Products($M)
15453.0
Oxytetracycline & Licorice products and TCMD($M)
40.938.038.450.760.834.423.3
Insurance Business($M)
30.9
AI Solutions($M)
22.5
Heparin products and Sausage casing($M)
8.888.949.5811.212.011.39.87
Fertilizer($M)
3.202.953.292.612.542.442.15

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics
  • Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).

Data updated 2026-07-21.

See a number that looks wrong?